The Efficacy and Safety of Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis: A Pilot Study

Gholamreza Shamseii, Fatemeh Houshmand, Ahmad Ahmadzadeh Deylami, Armita Valizadeh, Shahram Rafie, Maryam Moradi

1Department of Neurology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
2Department of Anatomy, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
3Department of Biostatistics and Epidemiology, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Article info
Article History:
Received: October 7, 2021
Revised: December 29, 2021
Accepted: January 7, 2022
epublISHED: January 8, 2022

Keywords:
ALS, MSCs, Mesenchymal stromal cells, Amyotrophic lateral sclerosis, Transplantation

Abstract
Purpose: Amyotrophic lateral sclerosis (ALS) is an uncommon and aggressive neurodegenerative disorder that influences the lower and upper motor neurons. There are low eligible drugs for ALS treatment; in this regard, supplemental and replacement treatments are essential. There are relative studies in the field of mesenchymal stromal cells (MSCs) therapy in ALS, but the different methods, differently used medium, and difference in follow-up periods affect the outcome treatment.

Methods: The current survey is a single-center, phase I clinical trial to evaluating the efficacy and safety of autologous bone marrow (BM)-derived MSCs through intrathecal administration in ALS patients. MNCs were isolated from BM specimens and cultured. The clinical outcome was evaluated based Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) Scale.

Results: Each patient received $15 \pm 3 \times 10^6$ cells through subarachnoid space. No adverse events (AEs) were detected. Just one patient experienced a mild headache after injection. Following injection, no new intradural cerebrospinal pathology transplant-related was observed. None of the patients’ pathologic disruptions following transplantation were detected by magnetic resonance imaging (MRI). The additional analyses have shown the average rate of ALSFRS-R score and forced vital capacity (FVC) reduction have decreased during 10 months following injection, from $-5.4 \pm 2.3$ to $-2 \pm 3.08$ ALSFRS-R points/period ($P = 0.014$) and $-12.6 \pm 5.22\%$ to $-4.8 \pm 14.72\%/period (P < 0.001)$, respectively.

Conclusion: These results have shown that autologous MSCs transplantation reduces the disease’s progression and has favorable safety.

Trial Registration: This study performed as a phase I clinical trial (code IRCT20200828048551N1).

Introduction
Amyotrophic lateral sclerosis (ALS) is an uncommon and aggressive neurodegenerative disorder that influences the lower and upper motor neurons. Among the motor neurons disorders, ALS is more common. There are two types of ALS: hereditary and sporadic; that the sporadic form is more prevalent. In the hereditary form which is accounts for 10% of patients; asexual chromosomes are the most common pattern of inheritance. Although the main pathogenesis of the disease is not definitely recognized known, nevertheless the contribution of autoimmune mechanisms cannot be ruled out. The prevalence of ALS has been estimated at 6 cases per 100 000. The occurrence of ALS with increasing age increases, and most of the cases are 60 years or older. In the case of sporadic ALS, this age range increases.

The spectrum of symptoms differs from muscle weakness to cognitive and behavioral signs, which can cause misdiagnosis. In accordance with clinical symptoms, ALS is categorized into two groups; spinal ALS and Bulbar ALS. In spinal ALS, patients become paralyzed or die within three to five years. The median survival duration after diagnosis, approximately 2-4 years, was reported. Despite, the recognizing prognosis factors, just 5% of patients live for 20 years or longer. Factors such as the age of onset symptoms at older age, lower Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS or ALSFRS-R) score, and early dysfunction of the respiratory muscles accompanied with lower survival have to influence on disease progression. Also, men are more susceptible than women to ALS.

There is no definitive treatment for ALS. Up to now,
due to invasive and fast disease progression, the current therapy approach is to reduce the severity of symptoms. In this regard, more recent attention has focused on providing treatment with considerable safety and efficacy. This causes a growing body of kinds of literature focusing on the different disorder pros.\textsuperscript{11-15} Despite progress in understanding the therapeutic target of ALS, but there is no data as a clinical trial.\textsuperscript{16} Although safety treatments have developed, but effective treatment has not yet been achieved.\textsuperscript{17} Cell therapy in neurology disorder has been widely used. Therapeutic effects of cell therapy have been shown in the treatment of neurology disorders such as Parkinson, Alzheimer, multiple sclerosis, stroke, and Huntington.\textsuperscript{14-20} The literature has recently emphasized the importance of mesenchymal stromal cells (MSCs) therapeutic effect in ALS. Although MSCs have less ability to proliferate and differentiate than embryonic stem cells and neuronal stem cells, because they are autologous, they have attracted a lot of attention and have been effective in treating a number of neurological diseases. In autologous MSCs therapy, the neuroprotection of MSCs protects the surviving motor neurons.\textsuperscript{7}

There are relative studies in the field of MSCs therapy in ALS, but the different methods, differently used medium, and difference in follow-up periods affect the treatment progression and outcome. Hence, more investigations are needed to validate this approach. The current survey aims to evaluate the safety and efficacy of autologous bone marrow (BM)-derived MSCs injection through intrathecal in ALS patients.

Methods

Study design
The current survey is a single-center, phase I clinical trial to evaluate the efficacy and safety of autologous BM-derived MSCs through intrathecal administration in ALS patients were recruited to the department of neurology. The study was based on the approval of the Medical Ethics Committee of Jundishapur Alvaz University (Reference Number: IR.AJUMS.REC.1398.904) and performed as a phase I clinical trial (code IRCT20200828048551N1). All participants assigned the consent form.

Study population
Selecting patients for the current study were based on the following inclusion criteria: age between 20 and 60 years old, the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score between 26 and 46, forced vital capacity (FVC) of more than 40% of the predicted value, and history of at least 3 months before screening riluzole treatment at the stable dose (50 mg, twice daily). Exclusion criteria were considered as previous treatment with stem cell therapy, pregnancy, breastfeeding, coagulopathy, gastrostomy, cardiovascular disease, hepatic or renal disorder, cancer, systemic infection, recurrent thromboembolic disease, tracheostomy ventilation, or noninvasive ventilation (NIV) for more than 12 hours per day, and the administration of any drug which influences the BM. All patients are assigned a consent form.

BM-derived mesenchymal stromal cells production
BM aspiration was performed under short general anesthesia with a puncture from the posterior superior iliac crest while the patient was lying in a left or a right lateral position. Approximately 200 mL of BM inocula was obtained from each patient.

Mononuclear cells (MNCs) were isolated from BM specimens; at first, the samples were diluted (1:1) with phosphate-buffered saline (PBS, pH 7.4, Gibco, BRL) next separated by using Ficoll (Biosera, France) and density gradient centrifuge (1500 rpm for 20 minutes). Then MNCs were cultured under standard conditions in a DMEM-F12 medium containing human serum (15%) and antibiotics in a 25 cm flask (day 0). The flasks were incubated in 5% CO2 and 37°C. To removing the non-adherent cells were washed using PBS. This process was repeated until the cells reached 80-90% confluent, then MSCs were harvested using trypsin enzyme (Gibco, BRL) and subcultured. The MSCs were analyzed with flow cytometry for markers and features described in International Society for Cellular Therapy guidelines.\textsuperscript{21}

Cell transplantation
Each patient received $15\pm3\times10^6$ cells through subarachnoid space using lumbar puncture at L2-3 or L3-4 levels. After transplantation, patients were closely monitored within 1 day for immediate adverse events (AE). The critical clinical findings, including respiratory and heart rate, blood pressure, and body temperature, were assessed every 6 hours. After 24 hours, if any AEs were not observed, patients were discharged.

Clinical assessment
The clinical outcome was evaluated based on ALSFRS-R.\textsuperscript{22} Respiratory failures account for one of the fatal complications of ALS. In this regard, in the present survey, respiratory function is evaluated by FVC routinely.\textsuperscript{23,24} To assess MSCs therapy safety, patients were monitored for AEs, including liver, kidney, and thyroid function, for 20 months (-10 months to +10 months) before transplantation conditions of all patients were evaluated. After transplantation, all patients were evaluated for AEs by magnetic resonance imaging (MRI).

Statistical analysis
Normality of data were checked by Kolmogorov-Smirnov test. T-test was used to compare baseline parameters after follow-up. The ANOVA test was used to compare the outcome of transplantation with time. Mann-Whitney was used to compare means. The significant P-value was considered <0.05. All data were analyzed by SPSS software (V24, 2017, USA).
Results and Discussion

Seven patients (5 males and 2 females) were recruited for this study. The mean age was 44.7 ± 9.01 years. All patients were diagnosed according to the El Escorial revised criteria. Two patients underwent a tracheostomy due to progressive respiratory failure before treatment and were excluded from the study. The baseline characteristics and functional changes of the initial 7 patients are described in Table 1. Five patients who matched the selection criteria were followed up. At -10 months, the mean of ALSFRS-R score and FVC were 32.2 ± 5.58 points and 55.2% ± 19.18, respectively. For safety evaluation, all patients were assessed regulatory during the following-up period. No AEs were detected in patients (Table 2). Just one patient experienced a mild headache after injection, which resolved with routine analgesics. Following injection, no new intradural cerebrospinal pathology transplant-related was observed. None of the patients’ pathologic disruptions following

Table 1. The clinical characteristic of patients at baseline

| Patients | Age (y) | Gender | Disease durationa | Disorder Typeb | ALSFRS-R score | FVC (%) | PEGc | Tracheostomyd | Deathc |
|----------|---------|--------|-------------------|----------------|----------------|---------|------|---------------|---------|
| 1        | 35      | M      | 30                | Spinal         | 30             | 55      | NO   | NO            | NO      |
| 2        | 53      | M      | 14                | Spinal         | 44             | 96      | NO   | NO            | NO      |
| 3        | 44      | F      | 24                | Spinal + bulbar| 29             | 42      | NO   | NO            | NO      |
| 4        | 53      | M      | 22                | Bulbar         | 34             | 59      | NO   | NO            | NO      |
| 5        | 32      | M      | 20                | Spinal         | 31             | 49      | NO   | NO            | NO      |
| 6*       | 42      | F      | 18                | Bulbar         | 31             | 46      | -2   | -2            | NO      |
| 7*       | 54      | M      | 34                | Spinal         | 27             | 40      | -1   | -1            | NO      |

Abbreviations: ALS: amyotrophic lateral sclerosis; ALSFRS-R: Revised ALS Functional Rating Scale; PEG: percutaneous endoscopic gastrostomy.

*Patients 6 and 7 were excluded because of insufficient long-term follow-up data (for the reasons of tracheostomy).

a Month from injection; b at enrollment (mon).

Table 2. Adverse effects after cell transplantation

| Adverse effect                          | Patient (n) | Duration (days) | Outcome |
|----------------------------------------|-------------|----------------|---------|
| General disorders and administration site condition |             |                |         |
| Influenza-like illness                  | 0           | No             | -       |
| Pyrexia                                | 0           | No             | -       |
| Pain                                   | 0           | No             | -       |
| Nervous system disorders               |             |                |         |
| Headache                               | 1           | 5              | Improved after treatment |
| Nausea and vomiting                    | 0           | No             | -       |
| Dizziness                              | 0           | No             | -       |
| Unconsciousness                        | 0           | No             | -       |
| Seizures                               | 0           | No             | -       |
| Vertigo                                | 0           | No             | -       |
| Visual impairment                      | 0           | No             | -       |
| Musculoskeletal and connective tissue disorders |             |                |         |
| Back pain                              | 0           | No             | -       |
| Arthralgia                             | 0           | No             | -       |
| General disorders administration site condition |             |                |         |
| Influenza-like illness                  | 0           | No             | -       |
| Pyrexia                                | 0           | No             | -       |
| Allergic reactions                     |             |                |         |
| Fever                                  | 0           | No             | -       |
| Anaphylaxis                            | 0           | No             | -       |
| Apnea                                  | 0           | No             | -       |
| Urticaria                              | 0           | No             | -       |
| Local adverse events                   |             |                |         |
| Infection                              | 0           | No             | -       |
| Phlebitis                              | 0           | No             | -       |
| Hematoma                               | 0           | No             | -       |
transplantation were not detected in patients by MRI. Two patients could not complete the follow-up period due to experiencing tracheostomy causes progressive respiratory failure and the efficacy was calculated for five patients. The site and route injection are important factors that can influence the safety and efficacy of treatment. Nabavi and colleagues carried out a clinical trial to compare the safety and efficacy of intravenous and intrathecal MSCs injections; they demonstrated without significant AEs, both injections are helpful in ALS cell therapy.26 Also, it was demonstrated in patients with widespread tissue damage, MSCs injection in different sites has the safety and efficacy with injection through the spinal cord.27 Hence, in the current investigation, the MSCs were administrated in a noninvasive way. Our findings have shown the single dose of MSCs injection through the intrathecal route without any life-threatening AEs increase the ALSFRS-R slope. This result is in accordance with Berry and colleagues and Syková and colleague’s results; they reported a single dose of MSCs injection to improve the ALSFRS-R slope than the placebo group.28,29

The additional analyses have shown the average rate of reduction of ALSFRS-R score and FVC have decreased during 10 months following MSCs transplantation versus the pretreatment period, from -5.4 ± 2.3 to -2 ± 3.08 ALSFRS-R points/period (P = 0.014) (Table 3, Figure 1) and -12.6 ± 5.22 % to -4.8 ± 14.72 %/period (Figure 2, Table 4) (P < 0.001), respectively. These results indicate that the autologous MSCs transplantation reduces the disease progression. Further analysis with linear regression has revealed that 43% of changes after transplantation have belonged to FVC, and this value for ALSFRS-R score was detected 65.7% (Table 5). The effect size of autologous MSCs transplantation was shown in Table 5.

The Pearson correlation coefficients were used to determine the association between ALSFRS-R score and FVC parameters before and after treatment. However, the significant differences were not seen (P = 0.096 and P = 0.227), respectively.

More recent attention has focused on providing usability of MSCs therapy in neurodegenerative disorders due to their unique abilities. There are some comparative studies conducted on the efficacy of MSCs therapy in ALS. However, the determination type of administration route, count of injecting cells, and several injections are technically challenging, so there is a need for more investigations in line with similar previous surveys. The present study was designed to determine the therapeutic safety and efficacy of intrathecal injection of autologous MSCs on ALS progress and outcome.

Neuroinflammation plays a key role in ALS pathogenesis. The imbalance between inflammatory and anti-inflammatory is one of the main pathogenesis in ALS. Analysis of the involved cytokines and chemokines

![Figure 1. The trend of the amyotrophic lateral sclerosis-functional rating scale (ALS-FRS) during 10 months follow-up.](image)

![Figure 2. The trend of forced vital capacity (FVC) during 10 months follow-up.](image)

| Table 3. ALSFRS-R score of all 5 ALS patients enrolled in the clinical trial |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Patient         | -10  | -6   | -3   | 0    | 3    | 6    | 10   |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| M               | M               | M               | M               | M               | M               | M               | M               |
| 1               | 30              | 29              | 27              | 26              | 28              | 28              | 28              |
| 2               | 44              | 42              | 39              | 35              | 34              | 33              | 30              |
| 3               | 29              | 27              | 27              | 26              | 28              | 28              | 26              |
| 4               | 34              | 32              | 31              | 29              | 29              | 27              | 27              |
| 5               | 31              | 29              | 28              | 25              | 24              | 23              | 20              |

* The negative symbol (·) before month indicating the period of pretreatment.

| Table 4. Forced vital capacity of All 5 ALS Patients Enrolled in the Clinical trial |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Patient         | -10  | -6   | -3   | 0    | 3    | 6    | 10   |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| M               | M               | M               | M               | M               | M               | M               | M               |
| 1               | 55              | 51              | 42              | 44              | 44              | 44              | 58              |
| 2               | 96              | 93              | 87              | 79              | 71              | 64              | 55              |
| 3               | 42              | 40              | 40              | 37              | 51              | 44              | 42              |
| 4               | 59              | 59              | 55              | 47              | 40              | 40              | 36              |
| 5               | 49              | 43              | 38              | 31              | 28              | 23              | 23              |

**Table 5. The regression analysis and effect size for FVC and ALSFRS-R score**

|     | Group 1 (SD) | Group 2 (SD) | Effect Size Cohen’s d (95% CI) | R     | R²   | Adjusted R² |
|-----|--------------|--------------|-------------------------------|-------|------|-------------|
| FVC | 12.6 (5.22)  | 4.8 (14.72)  | -0.706                        | 0.659 | 0.434| 0.245       |
| ALSFRS-R score | 5.4 (2.30)  | 2.3 (3.08)  | -1.251                        | 0.810 | 0.657| 0.542       |

Abbreviations: ALSFRS-R: Revised ALS Functional Rating Scale; FVC: forced vital capacity; CI: confidence interval; MSCs: mesenchymal stromal cells; SD: standard deviation.
in ALS revealed CCL2, CXCL8, CCL4, and Transforming growth factor-β (TGF-β) have negatively correlated with ALSFRS-R score and disease progression. In this regard, it was demonstrated MSCs, by increasing TGF-β secreting, disrupt the motor neuron loss in ALS. So, the therapeutic strategy to balance inflammatory and anti-inflammatory cytokines causes a growing body of literature in this issue.

TAR DNA-binding protein 43 (TDP-43) is a protein which normally located in nuclei cells. In a considerable number of ALS cases, the TDP-43 in insoluble shortened form accumulates in the cell cytoplasm. In the hereditary form of ALS, the mutation in the C9orf72 gene causes neurodegenerative. This gene defect with influencing TDP-43 protein contributes to ALS pathogenesis.

These aggregations change the shape of the membrane and the nucleus pores, thereby disrupting the entry of important proteins into the nucleus and the exit of RNA from the nucleus. Additionally, these accumulations with upregulation of nuclear factor κB (NF-κB) and type I interferon (IFN) pathways and with involving neuroinflammation contributes to ALS pathogenesis.

Monocyte chemoattractant protein-1 (MCP-1) by disrupting motor neurons contribute to ALS pathogenesis. By decreasing MCP-1, the severity of ALS symptoms is reduced; subsequently, the ALSFRS-R score decreases. MSCs by decreasing MCP in CSF-1 andstromal cell-derived factor-1α (SDF-1) after transplantation and effect on ALSFRS-S score. Inflammatory cytokines by increasing MCP-1 Intensifies and causes fast progression in ALS patients, decreases the average rate of reduction of ALSFRS-R score and FVC after single-dose MSCs injection in our result can be explained by this and confirms that by repeated injection, the number of cells increases in CSF for a longer time and can be more therapeutic than single-dose.

In a study that determined whom ALS patients respond better to autologous MSCs transplantation, Kim and colleagues isolated MSCs from responder and non-responder and induction to mice “to measure their lifespans locomotor activity, and motor neuron numbers.” Their findings have shown that TGF-β, vascular endothelial growth factor, and angiogenin are higher in responders than non-responders; in fact, these cytokines can be used as a predictor for responding to the treatment and can be helpful to in decision whom patients need repeated injection. This finding is worth it and can justify the result of Siwek and colleagues that after repeated administration of MSCs, the favorable outcome was not observed.

MSCs, by reducing neuronal sensitivity to glutamate receptor ligands and altering gene expression, have a neuroprotection effect on damaged CNS. The absence of any AEs and no sign of abnormal cell growth after transplantation indicates that our intervention is safe and successfully improved ALS treatment.

**Conclusion**

The most prominent finding to emerge from this study is like the previous surveys that MSCs transplantation has favorable safety. In the current trial also demonstrated that MSCs auto transplantation is accompanied by slow disease progression in some ALS patients compare pretreatment period, indicating the efficacy of treatment. Unfortunately, the study did not include the cytokines and inflammation biomarkers before and after treatment. Further studies with repeated injection and evaluation predicting more biomarkers to therapy with a larger sample size are strongly suggested.

**Acknowledgments**

We wish to thank all our colleagues in Allied Health Sciences School, Ahvaz University of medical sciences.

**Competing Interests**

The authors declare no conflict of interest. All procedure performs in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1994 Helsinki Declaration and its later amendments or compare ethical strand.

**Ethical Approval**

The study was based on the approval of the Medical Ethics Committee of Jundishapur Ahvaz University (Reference Number: IR.AJUMS.REC.1398.904) and performed as a phase I clinical trial (identifier: IRCT20020082804531N1). All participants assigned the consent form.

**References**

1. Siwek T, Jezierska-Woźniak K, Maksymowicz S, Barczewska M, Sowa M, Badowska W, et al. Repeat administration of bone marrow-derived mesenchymal stem cells for treatment of amyotrophic lateral sclerosis. Med Sci Monit 2020;26:e927484. doi: 10.12659/msm.927484

2. Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc 2018;93(11):1617-28. doi: 10.1016/j.mayocp.2018.04.007

3. Ajroud-Driss S, Siddique T, Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochir Biophys Acta 2015;1852/4:679-84. doi: 10.1016/j.bbadis.2014.08.010

4. Ralli M, Lambiase A, Artico M, de Vincentiis M, Greco A. Amyotrophic lateral sclerosis: autoimmune pathogenic mechanisms, clinical features, and therapeutic perspectives. Isr Med Assoc J 2019;21(7):438-43.

5. Tallbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol 2016;138:222-38. doi: 10.1016/b978-0-12-802973-2.00013-6

6. Mehta P, Kaye W, Raymond J, Wu R, Larson T, Punjani R, et al. Prevalence of amyotrophic lateral sclerosis - United States, 2014. MMWR Morb Mortal Wkly Rep 2018;67(7):216-8. doi: 10.15585/mmwr.mm6707a3

7. Niedermeyer S, Murr M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest 2019;155(2):401-8. doi: 10.1016/j.chest.2018.06.035

8. Logroscino G, Traynor BJ, Hardiman O, Chib A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81(4):385-90. doi: 10.1136/jnnp.2009.183525

9. Hulisz D. Amyotrophic lateral sclerosis: disease state overview. Am J Manag Care 2018;24(15 Suppl:S320-S6.

10. Palese F, Sartori A, Verriello L, Kos S, Passadore P, Manganotti Palese F, Sartori A, Verriello L, Kos S, Passadore P, Manganotti
P, et al. Epidemiology of amyotrophic lateral sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002-2014: a retrospective population-based study. *Amyotroph Lateral Scler Frontotemporal Degener* 2019;20(1-2):90-9. doi: 10.1080/21678421.2018.1511732

11. van Groenestijn AC, Schröder CD, van Eijk RPA, Veldink JH, Kruijt-van-den Reemen ET, Groothuis JT, et al. Aerobic exercise therapy in ambulatory patients with ALS: A randomized controlled trial. *Neuromechanics* 2019;33(2):153-64. doi: 10.1177/1459683618792651

12. Biféri MG, Cohen-Tannoudji M, Cappelletto A, Giroux B, Roda M, Astord S, et al. A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model. *Mol Ther* 2017;25(9):2038-52. doi: 10.1016/j.ymthe.2017.05.017

13. Miyoshi S, Tezuka T, Arimitsu S, Tomono T, Okada T, Yamanashi Y. DOK7 gene therapy enhances motor activity and life span in ALS model mice. *EMBO Mol Med* 2017;9(7):880-9. doi: 10.15252/emmm.201607298

14. Yamashita T, Kwak S. Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS. *NeuroRes* 2019;144:4-13. doi: 10.1016/j.neures.2018.06.004

15. Park JM, Kim SY, Park D, Park JS. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. *Neural Sci* 2020;41(1):119-23. doi: 10.1002/brb3.637

16. Palomo V, Nozal V, Rojas-Prats E, Gil C, Martinez A. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. *Br J Pharmacol* 2019;178(6):1316-31. doi: 10.1111/bjp.15221

17. Kulin A, Medina-Paraiso E, Ishizaki K, Kim A, Zhang Y, Saita T, et al. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. *Amyotroph Lateral Scler Frontotemporal Degener* 2017;18(1-sup):71-9. doi: 10.1080/21678421.2017.153770

18. Alipour M, Nabavi SM, Arab L, Jarooghj T, Abbasi F, Mardpour S, et al. Safety, feasibility of intravenous and intrathecal injection of autologous bone marrow derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: an open label phase I clinical trial. *Cell J* 2019;20(4):592-8. doi: 10.22074/cell.2019.5370

19. Siwek T, Makowszowic W, Barczewska M, Grabarczyk L, Sowa M, Jezierska-Wozniak K, et al. Mesenchymal stem cell (MSC) transplantation in patients with amyotrophic lateral sclerosis (ALS): is there a “responder population”? *J Neural Neurosci* 2018;9(3):260. doi: 10.21767/2171-6625.1000260

20. Berry JD, Cutkovicz ME, Windebank AJ, Staff NP, Owegi M, Nicholson K, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. *Neurology* 2019;93(24):e2294-e305. doi: 10.1212/wnl.0000000000008620

21. Sykova E, Rychmach F, Drahonířová I, Konrádová S, Růžičková K, Voleš, J, et al. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase IIa clinical trial. *Cell Transplant* 2017;26(4):647-58. doi: 10.3727/096396916X693716

22. Tateishi T, Yamasaki R, Tanaka M, Matsushima T, Kikuchi H, Isobe N, et al. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. *J Neuroimmunol* 2010;222(1-2):76-81. doi: 10.1016/j.jneuroim.2010.03.004

23. Shariati A, Nemati R, Sadeghpiour Y, Yaghoubi Y, Baghbanl, R. Javid, K, et al. Mesenchymal stromal cells (MSCs) for neurodegenerative disease: a promising frontier. *Eur J Cell Biol* 2020;99(6):151097. doi: 10.1016/j.ejcb.2020.151097

24. Berning BA, Walker AK. The pathobiology of TDP-43 C-terminal fragments in ALS and FTD. *Front Neurosci* 2019;13:335. doi: 10.3389/fnins.2019.00335

25. St Martin JL, Wang L, Kriepel Z. Toxicity in ALS: TDP-43 modifiers and C9orf72. *Neurosci Lett* 2020;716:134621. doi: 10.1016/j.neulet.2019.134621

26. Yang Y, Halliday GM, Kiernan MC, Tan RH. TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. *Neurology* 2019;93(19):e1748-e55. doi: 10.1212/wnl.0000000000008439

27. Bury JJ, Highley JR, Cooper-Knoke J, Goodall EF, Higginbottom A, McDermott CJ, et al. Oligogenic inheritance of optineurin (OPTN) and C9orf72 mutations in ALS highlights localisation of OPTN in the TDP-43-negative inclusions of C9orf72-ALS. *Neuropathology* 2016;36(2):125-34. doi: 10.1111/neup.12240

28. Yu CH, Davidson S, Harapap CR, Hilton JB, Mlodzianowski MJ, Laahamonihunk P, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. *Cell* 2018;170(3):636-49.e18. doi: 10.1016/j.cell.2018.09.020

29. Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis. *Front Immunol* 2018;9:2122. doi: 10.3389/fimmu.2018.02122

30. Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. *Eur J Cell Biol* 2020;99(6):151097. doi: 10.1016/j.ejcb.2020.151097
40. Kim HY, Kim H, Oh KW, Oh SI, Koh SH, Baik W, et al. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study. *Stem Cells* 2014;32(10):2724-31. doi: 10.1002/stem.1770

41. Voulgari-Kokota A, Fairless R, Karamita M, KyrargyriV, Tseveleki V, Evangelidou M, et al. Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. *Exp Neurol* 2012;236(1):161-70. doi: 10.1016/j.expneurol.2012.04.011